1. Home
  2. DOW vs NTRA Comparison

DOW vs NTRA Comparison

Compare DOW & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dow Inc.

DOW

Dow Inc.

HOLD

Current Price

$28.87

Market Cap

27.8B

Sector

Industrials

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$263.76

Market Cap

29.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DOW
NTRA
Founded
1897
2003
Country
United States
United States
Employees
35700
N/A
Industry
Major Chemicals
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.8B
29.1B
IPO Year
2018
2015

Fundamental Metrics

Financial Performance
Metric
DOW
NTRA
Price
$28.87
$263.76
Analyst Decision
Buy
Strong Buy
Analyst Count
15
15
Target Price
$39.13
$259.07
AVG Volume (30 Days)
11.8M
1.4M
Earning Date
04-23-2026
05-07-2026
Dividend Yield
3.54%
N/A
EPS Growth
N/A
0.65
EPS
N/A
N/A
Revenue
$39,968,000,000.00
$210,939,000.00
Revenue This Year
$5.40
$18.08
Revenue Next Year
$2.33
$19.65
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$20.40
$131.81
52 Week High
$42.74
$271.47

Technical Indicators

Market Signals
Indicator
DOW
NTRA
Relative Strength Index (RSI) 22.61 74.25
Support Level $22.48 $186.96
Resistance Level $29.09 N/A
Average True Range (ATR) 1.24 12.70
MACD -0.35 4.60
Stochastic Oscillator 6.27 88.32

Price Performance

Historical Comparison
DOW
NTRA

About DOW Dow Inc.

Dow Chemical is a diversified global chemicals producer formed in 2019 as a result of the DowDuPont merger and subsequent separations. The firm is a leading producer of several chemicals, including polyethylene, ethylene oxide, and silicone rubber. Its products have numerous applications in consumer and industrial end markets.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: